Clinical Outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome.

IF 1.7 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2023-01-01 Epub Date: 2023-07-29 DOI:10.1159/000531831

Ilana Levy Yurkovski, Lior Rokach, Guy Melamed, Hillel Alapi, Sivan Gazit, Tal Patalon, Tamar Tadmor

{"title":"Clinical Outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome.","authors":"Ilana Levy Yurkovski, Lior Rokach, Guy Melamed, Hillel Alapi, Sivan Gazit, Tal Patalon, Tamar Tadmor","doi":"10.1159/000531831","DOIUrl":null,"url":null,"abstract":"Introduction: Haemato-oncologic patients are more susceptible to severe infections with SARS-CoV-2. We aimed to assess the clinical outcomes of SARS-CoV-2 infection among patients with Mycosis Fungoides and Sezary Syndrome (MF/SS).Methods: The data were retrieved from anonymized electronic medical records of Maccabi Healthcare Services (MHS), the second-largest healthcare organization in Israel. Patients diagnosed with MF/SS were included in the study. COVID-19 PCR test results together with sociodemographic and clinical data were extracted and analyzed to evaluate the association of COVID-19 with clinical outcomes.Results: In the period of 2020-2022, 1,472 MF/SS patients were included in the study. Among them, 768 (52%) had SARS-CoV-2 infection. The hospitalization rate was 2.9% and infection by the Delta variant was associated with the highest hospitalization rate (7.7%). The hospitalization rate was lower among fully vaccinated patients (p = 0.032) but higher for patients older than 65 (p < 0.001) and patients with SS (vs. MF) (p < 0.001) or COPD (p = 0.024) diagnosis. There was a tendency for decreased hospitalization among patients treated with nirmatrelvir + ritonavir within 5 days of infection, with a 79% risk reduction, although it was not statistically significant (p = 0.164).Conclusion: Patients with MF/SS do not necessarily have worse COVID-19 outcomes compared to the general population.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"497-504"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251663/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000531831","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Haemato-oncologic patients are more susceptible to severe infections with SARS-CoV-2. We aimed to assess the clinical outcomes of SARS-CoV-2 infection among patients with Mycosis Fungoides and Sezary Syndrome (MF/SS).

Methods: The data were retrieved from anonymized electronic medical records of Maccabi Healthcare Services (MHS), the second-largest healthcare organization in Israel. Patients diagnosed with MF/SS were included in the study. COVID-19 PCR test results together with sociodemographic and clinical data were extracted and analyzed to evaluate the association of COVID-19 with clinical outcomes.

Results: In the period of 2020-2022, 1,472 MF/SS patients were included in the study. Among them, 768 (52%) had SARS-CoV-2 infection. The hospitalization rate was 2.9% and infection by the Delta variant was associated with the highest hospitalization rate (7.7%). The hospitalization rate was lower among fully vaccinated patients (p = 0.032) but higher for patients older than 65 (p < 0.001) and patients with SS (vs. MF) (p < 0.001) or COPD (p = 0.024) diagnosis. There was a tendency for decreased hospitalization among patients treated with nirmatrelvir + ritonavir within 5 days of infection, with a 79% risk reduction, although it was not statistically significant (p = 0.164).

Conclusion: Patients with MF/SS do not necessarily have worse COVID-19 outcomes compared to the general population.

查看原文本刊更多论文

COVID-19 在真菌病和塞扎里综合征中的临床疗效

导言血液肿瘤患者更容易受到SARS-CoV-2的严重感染。我们旨在评估真菌病和塞扎里综合征（MF/SS）患者感染 SARS-CoV-2 后的临床结果：数据取自以色列第二大医疗机构马卡比医疗服务公司（Maccabi Healthcare Services，MHS）的匿名电子病历。被诊断为 MF/SS 的患者被纳入研究范围。研究人员提取并分析了 COVID-19 PCR 检测结果以及社会人口学和临床数据，以评估 COVID-19 与临床结果的关联：结果：2020-2022年间，共有1,472名MF/SS患者纳入研究。其中，768 人（52%）感染了 SARS-CoV-2。住院率为 2.9%，而感染三角洲变种的住院率最高（7.7%）。完全接种疫苗的患者的住院率较低（p = 0.032），但 65 岁以上的患者（p < 0.001）和确诊为 SS（相对于 MF）（p < 0.001）或 COPD（p = 0.024）的患者的住院率较高。在感染后5天内接受尼尔马特韦+利托那韦治疗的患者住院率有下降趋势，风险降低了79%，但并无统计学意义（p = 0.164）：结论：与普通人群相比，MF/SS 患者的 COVID-19 结果并不一定更差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.